Patent 11230588 was granted and assigned to ALPINE IMMUNE SCIENCES, INC. on January, 2022 by the United States Patent and Trademark Office.
Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.